Comorbidity in head and neck cancer

A critical appraisal and recommendations for practice

Vinidh Paleri, Richard G. Wight, Carl E. Silver, Missak Haigentz, Robert P. Takes, Patrick J. Bradley, Alessandra Rinaldo, Alvaro Sanabria, Stanisław Bień, Alfio Ferlito

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Comorbidity, the presence of additional illnesses unrelated to the tumor, has a significant impact on the prognosis of patients with head and neck cancer. In these patients, tobacco and alcohol abuse contributes greatly to comorbidity. Several instruments have been used to quantify comorbidity including Adult Comorbidity Evaluation 27 (ACE 27), Charlson Index (CI) and Cumulative Illness Rating Scale. The ACE 27 and CI are the most frequently used indices. Information on comorbidity at the time of diagnosis can be abstracted from patient records. Self-reporting is less reliable than record review. Functional status is not a reliable substitute for comorbidity evaluation as a prognostic measure. Severity as well as the presence of a condition is required for a good predictive instrument. Comorbidity increases mortality in patients with head and neck cancer, and this effect is greater in the early years following treatment. In addition to reducing overall survival, many studies have shown that comorbidity influences disease-specific survival negatively, most likely because patients with high comorbidity tend to have delay in diagnosis, often presenting with advanced stage tumors, and the comorbidity may also prompt less aggressive treatment. The impact of comorbidity on survival is greater in younger than in older patients, although it affects both. For specific tumor sites, comorbidity has been shown to negatively influence prognosis in oral, oropharyngeal, laryngeal and salivary gland tumors. Several studies have reported higher incidence and increased severity of treatment complications in patients with high comorbidity burden. Studies have demonstrated a negative impact of comorbidity on quality of life, and increased cost of treatment with higher degree of comorbidity. Our review of the literature suggests that routine collection of comorbidity data will be important in the analysis of survival, quality of life and functional outcomes after treatment as comorbidity has an impact on all of the above. These data should be integrated with tumor-specific staging systems in order to develop better instruments for prognostication, as well as comparing results of different treatment regimens and institutions.

Original languageEnglish (US)
Pages (from-to)712-719
Number of pages8
JournalOral Oncology
Volume46
Issue number10
DOIs
StatePublished - Oct 2010

Fingerprint

Head and Neck Neoplasms
Comorbidity
Survival
Quality of Life
Neoplasms
Glandular and Epithelial Neoplasms
Neoplasm Staging
Therapeutics
Survival Analysis
Health Care Costs

Keywords

  • Comorbidity
  • Head and neck cancer
  • Morbidity
  • Mortality
  • Oral cancer
  • Prognosis
  • Quality of life
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Oral Surgery
  • Cancer Research

Cite this

Paleri, V., Wight, R. G., Silver, C. E., Haigentz, M., Takes, R. P., Bradley, P. J., ... Ferlito, A. (2010). Comorbidity in head and neck cancer: A critical appraisal and recommendations for practice. Oral Oncology, 46(10), 712-719. https://doi.org/10.1016/j.oraloncology.2010.07.008

Comorbidity in head and neck cancer : A critical appraisal and recommendations for practice. / Paleri, Vinidh; Wight, Richard G.; Silver, Carl E.; Haigentz, Missak; Takes, Robert P.; Bradley, Patrick J.; Rinaldo, Alessandra; Sanabria, Alvaro; Bień, Stanisław; Ferlito, Alfio.

In: Oral Oncology, Vol. 46, No. 10, 10.2010, p. 712-719.

Research output: Contribution to journalArticle

Paleri, V, Wight, RG, Silver, CE, Haigentz, M, Takes, RP, Bradley, PJ, Rinaldo, A, Sanabria, A, Bień, S & Ferlito, A 2010, 'Comorbidity in head and neck cancer: A critical appraisal and recommendations for practice', Oral Oncology, vol. 46, no. 10, pp. 712-719. https://doi.org/10.1016/j.oraloncology.2010.07.008
Paleri, Vinidh ; Wight, Richard G. ; Silver, Carl E. ; Haigentz, Missak ; Takes, Robert P. ; Bradley, Patrick J. ; Rinaldo, Alessandra ; Sanabria, Alvaro ; Bień, Stanisław ; Ferlito, Alfio. / Comorbidity in head and neck cancer : A critical appraisal and recommendations for practice. In: Oral Oncology. 2010 ; Vol. 46, No. 10. pp. 712-719.
@article{927e336f13e242f28bce964b12bb354b,
title = "Comorbidity in head and neck cancer: A critical appraisal and recommendations for practice",
abstract = "Comorbidity, the presence of additional illnesses unrelated to the tumor, has a significant impact on the prognosis of patients with head and neck cancer. In these patients, tobacco and alcohol abuse contributes greatly to comorbidity. Several instruments have been used to quantify comorbidity including Adult Comorbidity Evaluation 27 (ACE 27), Charlson Index (CI) and Cumulative Illness Rating Scale. The ACE 27 and CI are the most frequently used indices. Information on comorbidity at the time of diagnosis can be abstracted from patient records. Self-reporting is less reliable than record review. Functional status is not a reliable substitute for comorbidity evaluation as a prognostic measure. Severity as well as the presence of a condition is required for a good predictive instrument. Comorbidity increases mortality in patients with head and neck cancer, and this effect is greater in the early years following treatment. In addition to reducing overall survival, many studies have shown that comorbidity influences disease-specific survival negatively, most likely because patients with high comorbidity tend to have delay in diagnosis, often presenting with advanced stage tumors, and the comorbidity may also prompt less aggressive treatment. The impact of comorbidity on survival is greater in younger than in older patients, although it affects both. For specific tumor sites, comorbidity has been shown to negatively influence prognosis in oral, oropharyngeal, laryngeal and salivary gland tumors. Several studies have reported higher incidence and increased severity of treatment complications in patients with high comorbidity burden. Studies have demonstrated a negative impact of comorbidity on quality of life, and increased cost of treatment with higher degree of comorbidity. Our review of the literature suggests that routine collection of comorbidity data will be important in the analysis of survival, quality of life and functional outcomes after treatment as comorbidity has an impact on all of the above. These data should be integrated with tumor-specific staging systems in order to develop better instruments for prognostication, as well as comparing results of different treatment regimens and institutions.",
keywords = "Comorbidity, Head and neck cancer, Morbidity, Mortality, Oral cancer, Prognosis, Quality of life, Survival",
author = "Vinidh Paleri and Wight, {Richard G.} and Silver, {Carl E.} and Missak Haigentz and Takes, {Robert P.} and Bradley, {Patrick J.} and Alessandra Rinaldo and Alvaro Sanabria and Stanisław Bień and Alfio Ferlito",
year = "2010",
month = "10",
doi = "10.1016/j.oraloncology.2010.07.008",
language = "English (US)",
volume = "46",
pages = "712--719",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Comorbidity in head and neck cancer

T2 - A critical appraisal and recommendations for practice

AU - Paleri, Vinidh

AU - Wight, Richard G.

AU - Silver, Carl E.

AU - Haigentz, Missak

AU - Takes, Robert P.

AU - Bradley, Patrick J.

AU - Rinaldo, Alessandra

AU - Sanabria, Alvaro

AU - Bień, Stanisław

AU - Ferlito, Alfio

PY - 2010/10

Y1 - 2010/10

N2 - Comorbidity, the presence of additional illnesses unrelated to the tumor, has a significant impact on the prognosis of patients with head and neck cancer. In these patients, tobacco and alcohol abuse contributes greatly to comorbidity. Several instruments have been used to quantify comorbidity including Adult Comorbidity Evaluation 27 (ACE 27), Charlson Index (CI) and Cumulative Illness Rating Scale. The ACE 27 and CI are the most frequently used indices. Information on comorbidity at the time of diagnosis can be abstracted from patient records. Self-reporting is less reliable than record review. Functional status is not a reliable substitute for comorbidity evaluation as a prognostic measure. Severity as well as the presence of a condition is required for a good predictive instrument. Comorbidity increases mortality in patients with head and neck cancer, and this effect is greater in the early years following treatment. In addition to reducing overall survival, many studies have shown that comorbidity influences disease-specific survival negatively, most likely because patients with high comorbidity tend to have delay in diagnosis, often presenting with advanced stage tumors, and the comorbidity may also prompt less aggressive treatment. The impact of comorbidity on survival is greater in younger than in older patients, although it affects both. For specific tumor sites, comorbidity has been shown to negatively influence prognosis in oral, oropharyngeal, laryngeal and salivary gland tumors. Several studies have reported higher incidence and increased severity of treatment complications in patients with high comorbidity burden. Studies have demonstrated a negative impact of comorbidity on quality of life, and increased cost of treatment with higher degree of comorbidity. Our review of the literature suggests that routine collection of comorbidity data will be important in the analysis of survival, quality of life and functional outcomes after treatment as comorbidity has an impact on all of the above. These data should be integrated with tumor-specific staging systems in order to develop better instruments for prognostication, as well as comparing results of different treatment regimens and institutions.

AB - Comorbidity, the presence of additional illnesses unrelated to the tumor, has a significant impact on the prognosis of patients with head and neck cancer. In these patients, tobacco and alcohol abuse contributes greatly to comorbidity. Several instruments have been used to quantify comorbidity including Adult Comorbidity Evaluation 27 (ACE 27), Charlson Index (CI) and Cumulative Illness Rating Scale. The ACE 27 and CI are the most frequently used indices. Information on comorbidity at the time of diagnosis can be abstracted from patient records. Self-reporting is less reliable than record review. Functional status is not a reliable substitute for comorbidity evaluation as a prognostic measure. Severity as well as the presence of a condition is required for a good predictive instrument. Comorbidity increases mortality in patients with head and neck cancer, and this effect is greater in the early years following treatment. In addition to reducing overall survival, many studies have shown that comorbidity influences disease-specific survival negatively, most likely because patients with high comorbidity tend to have delay in diagnosis, often presenting with advanced stage tumors, and the comorbidity may also prompt less aggressive treatment. The impact of comorbidity on survival is greater in younger than in older patients, although it affects both. For specific tumor sites, comorbidity has been shown to negatively influence prognosis in oral, oropharyngeal, laryngeal and salivary gland tumors. Several studies have reported higher incidence and increased severity of treatment complications in patients with high comorbidity burden. Studies have demonstrated a negative impact of comorbidity on quality of life, and increased cost of treatment with higher degree of comorbidity. Our review of the literature suggests that routine collection of comorbidity data will be important in the analysis of survival, quality of life and functional outcomes after treatment as comorbidity has an impact on all of the above. These data should be integrated with tumor-specific staging systems in order to develop better instruments for prognostication, as well as comparing results of different treatment regimens and institutions.

KW - Comorbidity

KW - Head and neck cancer

KW - Morbidity

KW - Mortality

KW - Oral cancer

KW - Prognosis

KW - Quality of life

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=77956152928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956152928&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2010.07.008

DO - 10.1016/j.oraloncology.2010.07.008

M3 - Article

VL - 46

SP - 712

EP - 719

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 10

ER -